Wu, Ming-FangMing-FangWuChang, Ya-HsuanYa-HsuanChangChen, Hsuan-YuHsuan-YuChenCHAO-CHI HOHUEI-WEN CHEN2023-05-302023-05-302023-05-090929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/631513Osimertinib (OSI), a third-generation tyrosine kinase inhibitor (TKI), efficiently benefits lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor (EGFR) mutations. However, combined OSI and immune checkpoint inhibitor in EGFR-mutant patients increases the incidence of interstitial lung disease (ILD), although the mechanism is unknown. Here, we investigated the interaction between dendritic cells (DCs), a potential critical player in ILD, and OSI. Seventeen LUAD patients received TKI therapy, and only the OSI therapy group (N = 10) showed a significant increase in CD40 and CD83 on immature DCs (iDCs), and an elevated trend for both markers on mature DCs (mDCs) during short- and long-term OSI therapy. Our results indicated that OSI therapy may potentially activate DC functions, which might increase the potential immune toxicity when combined with onco-immunotherapy.enCD40; CD83; Dendritic cells; Lung adenocarcinoma; Osimertinib[SDGs]SDG3journal article10.1016/j.jfma.2023.04.018371696572-s2.0-85158031598https://api.elsevier.com/content/abstract/scopus_id/85158031598